| Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015) |
40 |
| Targeting FGFR pathway in breast cancer |
27 |
| Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients |
21 |
| HER2-positive breast cancer: Current and new therapeutic strategies |
20 |
| Outcomes of immediate versus delayed breast reconstruction: Results of a multicenter prospective study |
18 |
| Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers |
17 |
| Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management |
17 |
| Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review |
16 |
| Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival |
15 |
| Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia |
15 |
| Prevalence of pain in patients with breast cancer post-treatment: A systematic review |
14 |
| Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study |
13 |
| Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry |
13 |
| Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database |
12 |
| Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study |
12 |
| Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines |
12 |
| Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity |
12 |
| MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis |
12 |
| Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy |
11 |
| Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials |
11 |
| Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment) |
11 |
| An exploratory radiomics analysis on digital breast tomosynthesis in women with mammographically negative dense breasts |
11 |
| Nipple-sparing bilateral prophylactic mastectomy and immediate reconstruction with TiLoop (R) Bra mesh in BRCA1/2 mutation carriers: A prospective study of long-term and patient reported outcomes using the BREAST-Q |
11 |
| Immunotherapy in breast cancer: An introduction |
11 |
| Tumor infiltrating lymphocytes in early breast cancer |
11 |
| Meta-analysis of flap perfusion and donor site complications for breast reconstruction using pedicled versus free TRAM and DIEP flaps |
11 |
| Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study |
10 |
| The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients |
10 |
| Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry |
10 |
| Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy |
10 |
| The impact of legislation mandating breast density notification - Review of the evidence |
9 |
| Interval breast cancers in the 'screening with tomosynthesis or standard mammography' (STORM) population-based trial |
9 |
| Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer |
9 |
| T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer |
9 |
| Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis |
9 |
| Is chronic postsurgical pain surgery-induced? A study of persistent postoperative pain following breast reconstruction |
9 |
| Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study |
8 |
| A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with single stage implant reconstruction in the treatment of breast cancer |
8 |
| Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer |
8 |
| Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC) |
8 |
| Long non-coding RNA HOTAIR in circulatory exosomes is correlated with ErbB2/HER2 positivity in breast cancer |
8 |
| A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy |
8 |
| ErbB4 receptor polymorphism 2368A>C and risk of breast cancer |
8 |
| Recurrence in early breast cancer: Analysis of data from 765 Australian women treated between 1997 and 2015 |
8 |
| Physical activity levels after treatment for breast cancer: Two-year follow-up |
8 |
| Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based study |
7 |
| A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP |
7 |
| Mastectomy patterns, but not rates, are changing in the treatment of early breast cancer. Experience of a single European institution on 2315 consecutive patients |
7 |
| Homologous recombination deficiency in triple negative breast cancer |
7 |
| Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasis |
7 |
